Seeking Alpha

Galectin Therapeutics falls after big rally

  • Galectin Therapeutics (GALT -13.9%) is having a rough session.
  • The shares rose 76% late last week, as investors clamored for liver disease plays in the wake of Intercept Pharmaceuticals' monumental rally.
  • Today, the company announced the completion of patient enrollment "in the first cohort of a Phase 1 trial of GR-MD-02."
  • The study will evaluate the "safety, tolerability, and exploratory biomarkers for efficacy for single and multiple doses of GR-MD-02 when administered to patients with fatty liver disease with advanced fibrosis." (PR)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector